Allist Pharmaceuticals, Inc.

This early-stage study tests a new tablet, AST2303, in 120 adults with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow the disease. Participants take the pill and are …

This study tests a new drug called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug can shrink tumors and how safe it is. About 88 participants will take the drug daily, …

This study tests a daily pill called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR gene changes (PACC or L861Q). About 300 participants will be randomly assigned to either the pill or chemo. The goal is to se…

This study tests whether a new drug called furmonertinib, combined with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults with stable…